Hepatitis/MASH

Bodily fluids may serve as vectors for transmission for transmitting hepatitis C virus RNA in patients with a high viral load.

HIV is not associated with preterm delivery, though antiretroviral therapy is, but hepatitis C may be a potential risk factor.

Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Early detection is vital to more patients with hepatitis C virus being eligible for increasingly efficient direct-acting antiviral treatment options.

Tailoring hepatitis C treatments to shorten regimen length can reduce costs and ease burden for patients with limited insurance benefits.

Direct-acting antivirals are a costly but highly-effective class of drugs for the treatment of hepatitis C that can cure most cases.

One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

The epidemiology of hepatitis A has shifted from point-source outbreaks to outbreaks caused by person-to-person transmission.

People who inject drugs may still able to achieve a cure of hepatitis C virus infection with treatment with direct-acting antivirals.

Interferon lambda 4 represents a vulnerability that benefits hepatitis C virus to the detriment of humans.

Treatment regimens consisting of daclatasvir plus sofosbuvir plus ribavirin and velpatasvir/sofosbuvir plus ribavirin show similar cure rates in patients with hepatitis C virus genotype 2 and 3.

Targeting interleukin (IL)-17A and IL-22 proteins may help delay the development of hepatic fibrosis.

Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.

All-oral direct-acting antivirals had a significant effect on the clinical and economic outcomes of patients with hepatitis C virus in the 4 years following the approval of these treatments.

Hepatitis B virus infectivity can remain stable for up to 9 months and demonstrate high resilience to antiseptics.

Top news of the day from across the health care landscape.

Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.

Top news of the day from across the health care landscape.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.

Study investigates whether direct-acting antiviral drugs for hepatitis C virus increase the risk of developing hepatocellular carcinoma.

The national Veterans Health Administration Corporate Data Warehouse could be key in revealing accurate data on the use of direct-acting antivirals in the treatment of chronic hepatitis C virus.